HER2阳性早期乳腺癌患者的体重指数与体重变化:APHINITY试验亚组分析
该研究为APHINITY随机试验的探索性分析,评估BMI及体重变化与HER2阳性早期乳腺癌患者结局的关联。4787例患者中47%为超重/肥胖,超重/肥胖与更差的iDFS、DRFI和OS相关,而2年时体重变化与临床结局无关。
要点
- 超重/肥胖患者化疗中断更常见(14% vs 9%,p<0.001)。
- 超重/肥胖与更差iDFS(aHR 1.27;95%CI 1.06-1.52)、DFRI(aHR 1.32;95%CI 1.06-1.64)和OS(aHR 1.38;95%CI 1.08-1.77)相关。
- 2年时体重变化≥5.0%与临床结局无关。
核心结论
- 探索性分析结果提示,诊断时超重/肥胖与更差的生存结局相关。
研究设计与样本
- APHINITY试验(NCT01358877)的探索性分析,该随机试验比较辅助双靶与单靶HER2阻断联合化疗在HER2阳性早期乳腺癌中的疗效。
- 共纳入4787例患者,基线及随机后2年收集BMI。
- 患者按BMI<25 kg/m2(偏瘦/正常体重)和BMI≥25 kg/m2(超重/肥胖)分类。
主要发现
- 4787例患者中,2252例(47%)为超重/肥胖,2535例(53%)为偏瘦/正常体重。
- 超重/肥胖患者较偏瘦/正常体重患者化疗中断更常见(14% vs 9%,p<0.001)。
- 超重/肥胖患者较偏瘦/正常体重患者iDFS更差(aHR 1.27;95%CI 1.06-1.52)、DFRI更差(aHR 1.32;95%CI 1.06-1.64)、OS更差(aHR 1.38;95%CI 1.08-1.77)。
- 调整化疗中断后,超重/肥胖对iDFS的影响仍存在(iDFS aHR 1.26,95%CI 1.05-1.51;DRFI aHR 1.31,95%CI 1.06-1.63;OS aHR 1.35,95%CI 1.05-1.73)。
- 2年时体重变化与临床结局无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Body mass index (BMI) may affect prognosis in patients with breast cancer (BC). We assessed the association of BMI and weight changes with outcomes of patients with HER2-positive early BC included in the APHINITY trial. METHODS: This is an exploratory analysis of APHINITY (NCT01358877), randomized trial testing adjuvant dual vs. single HER2 blockade plus chemotherapy in HER2-positive early BC. BMI was collected at baseline and at two years after randomization. Patients were classified as underweight/normal weight (BMI<25 kg/m2) and overweight/obese (BMI≥25 kg/m2). The association of BMI with invasive disease-free survival (iDFS), distant recurrence-free interval (DRFI) and overall survival (OS) was investigated. Landmark approach was used to compare event for weight change ≥ 5.0 % at 2 years from baseline. RESULTS: Of 4787 patients included, 2252 (47 %) were overweight/obese and 2535 (53 %) underweight/normal weight. Patients who were overweight/obese had more often chemotherapy discontinuation compared to underweight/normal weight patients (14 % vs. 9 %, p < 0.001). Patients who were overweight/obese exhibited worse iDFS (adjusted hazard ratio [aHR] 1.27; 95 % CI 1.06-1.52), DFRI (aHR 1.32; 95 % CI 1.06-1.64) and OS (aHR 1.38; 95 %CI 1.08-1.77) than underweight/normal weight patients. This effect on iDFS remained after adjusting for chemotherapy discontinuation (iDFS aHR 1.26, 95 % CI 1.05-1.51; DRFI aHR 1.31, 95 % CI 1.06-1.63; OS aHR 1.35 95 % CI 1.05-1.73). Weight changes at 2 years were not associated with clinical outcomes. CONCLUSIONS: Our exploratory findings suggest that overweight/obesity at diagnosis was associated with worse survival outcomes.
引用
- Dauccia C, Alice Franzoi M, Martel S, et al. Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. Eur J Cancer. 2025. PMID: 40367619. doi:10.1016/j.ejca.2025.115489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。